Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1995 Apr 11;92(8):3283–3287. doi: 10.1073/pnas.92.8.3283

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine on visna virus infection in lambs: a model for in vivo testing of candidate anti-human immunodeficiency virus drugs.

H Thormar 1, G Georgsson 1, P A Pálsson 1, J Balzarini 1, L Naesens 1, S Torsteinsdóttir 1, E De Clercq 1
PMCID: PMC42150  PMID: 7724553

Abstract

The acyclic nucleoside phosphonate analog 9-(2-phosphonylmethoxyethyl)adenine (PMEA) was recently found to be effective as an inhibitor of visna virus replication and cytopathic effect in sheep choroid plexus cultures. To study whether PMEA also affects visna virus infection in sheep, two groups of four lambs each were inoculated intracerebrally with 10(6.3) TCID50 of visna virus strain KV1772 and treated subcutaneously three times a week with PMEA at 10 and 25 mg/kg, respectively. The treatment was begun on the day of virus inoculation and continued for 6 weeks. A group of four lambs were infected in the same way but were not treated. The lambs were bled weekly or biweekly and the leukocytes were tested for virus. At 7 weeks after infection, the animals were sacrificed, and cerebrospinal fluid (CSF) and samples of tissue from various areas of the brain and from lungs, spleen, and lymph nodes were collected for isolation of virus and for histopathologic examination. The PMEA treatment had a striking effect on visna virus infection, which was similar for both doses of the drug. Thus, the frequency of virus isolations was much lower in PMEA-treated than in untreated lambs. The difference was particularly pronounced in the blood, CSF, and brain tissue. Furthermore, CSF cell counts were much lower and inflammatory lesions in the brain were much less severe in the treated lambs than in the untreated controls. The results indicate that PMEA inhibits the propagation and spread of visna virus in infected lambs and prevents brain lesions, at least during early infection. The drug caused no noticeable side effects during the 6 weeks of treatment.

Full text

PDF
3283

Images in this article

3286Fig. 2
on p.3286

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrésson O. S., Elser J. E., Tobin G. J., Greenwood J. D., Gonda M. A., Georgsson G., Andrésdóttir V., Benediktsdóttir E., Carlsdóttir H. M., Mäntylä E. O. Nucleotide sequence and biological properties of a pathogenic proviral molecular clone of neurovirulent visna virus. Virology. 1993 Mar;193(1):89–105. doi: 10.1006/viro.1993.1106. [DOI] [PubMed] [Google Scholar]
  2. Balzarini J., Hao Z., Herdewijn P., Johns D. G., De Clercq E. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1499–1503. doi: 10.1073/pnas.88.4.1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Balzarini J., Holy A., Jindrich J., Dvorakova H., Hao Z., Snoeck R., Herdewijn P., Johns D. G., De Clercq E. 9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4961–4965. doi: 10.1073/pnas.88.11.4961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Balzarini J., Naesens L., De Clercq E. Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in vivo increases when it is less frequently administered. Int J Cancer. 1990 Aug 15;46(2):337–340. doi: 10.1002/ijc.2910460233. [DOI] [PubMed] [Google Scholar]
  5. Balzarini J., Naesens L., Herdewijn P., Rosenberg I., Holy A., Pauwels R., Baba M., Johns D. G., De Clercq E. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci U S A. 1989 Jan;86(1):332–336. doi: 10.1073/pnas.86.1.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Balzarini J., Naesens L., Slachmuylders J., Niphuis H., Rosenberg I., Holý A., Schellekens H., De Clercq E. 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. AIDS. 1991 Jan;5(1):21–28. doi: 10.1097/00002030-199101000-00003. [DOI] [PubMed] [Google Scholar]
  7. Balzarini J., Sobis H., Naesens L., Vandeputte M., De Clercq E. Inhibitory effects of 9-(2-phosphonylmethoxyethyl)adenine and 3'-azido-2',3'-dideoxythymidine on tumor development in mice inoculated intracerebrally with Moloney murine sarcoma virus. Int J Cancer. 1990 Mar 15;45(3):486–489. doi: 10.1002/ijc.2910450319. [DOI] [PubMed] [Google Scholar]
  8. De Clercq E., Holý A., Rosenberg I. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrob Agents Chemother. 1989 Feb;33(2):185–191. doi: 10.1128/aac.33.2.185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. De Clercq E., Holý A., Rosenberg I., Sakuma T., Balzarini J., Maudgal P. C. A novel selective broad-spectrum anti-DNA virus agent. Nature. 1986 Oct 2;323(6087):464–467. doi: 10.1038/323464a0. [DOI] [PubMed] [Google Scholar]
  10. Egberink H., Borst M., Niphuis H., Balzarini J., Neu H., Schellekens H., De Clercq E., Horzinek M., Koolen M. Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Proc Natl Acad Sci U S A. 1990 Apr;87(8):3087–3091. doi: 10.1073/pnas.87.8.3087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gangemi J. D., Cozens R. M., De Clercq E., Balzarini J., Hochkeppel H. K. 9-(2-Phosphonylmethoxyethyl)adenine in the treatment of murine acquired immunodeficiency disease and opportunistic herpes simplex virus infections. Antimicrob Agents Chemother. 1989 Nov;33(11):1864–1868. doi: 10.1128/aac.33.11.1864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gendelman H. E., Narayan O., Kennedy-Stoskopf S., Kennedy P. G., Ghotbi Z., Clements J. E., Stanley J., Pezeshkpour G. Tropism of sheep lentiviruses for monocytes: susceptibility to infection and virus gene expression increase during maturation of monocytes to macrophages. J Virol. 1986 Apr;58(1):67–74. doi: 10.1128/jvi.58.1.67-74.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gonda M. A., Wong-Staal F., Gallo R. C., Clements J. E., Narayan O., Gilden R. V. Sequence homology and morphologic similarity of HTLV-III and visna virus, a pathogenic lentivirus. Science. 1985 Jan 11;227(4683):173–177. doi: 10.1126/science.2981428. [DOI] [PubMed] [Google Scholar]
  14. Gray F., Lescs M. C., Keohane C., Paraire F., Marc B., Durigon M., Gherardi R. Early brain changes in HIV infection: neuropathological study of 11 HIV seropositive, non-AIDS cases. J Neuropathol Exp Neurol. 1992 Mar;51(2):177–185. doi: 10.1097/00005072-199203000-00007. [DOI] [PubMed] [Google Scholar]
  15. Naesens L., Balzarini J., De Clercq E. Acyclic adenine nucleoside phosphonates in plasma determined by high-performance liquid chromatography with fluorescence detection. Clin Chem. 1992 Apr;38(4):480–485. [PubMed] [Google Scholar]
  16. Naesens L., Balzarini J., De Clercq E. Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo. Antiviral Res. 1991 Jul;16(1):53–64. doi: 10.1016/0166-3542(91)90058-y. [DOI] [PubMed] [Google Scholar]
  17. Nathanson N., Panitch H., Palsson P. A., Petursson G., Georgsson G. Pathogenesis of visna. II. Effect of immunosuppression upon early central nervous system lesions. Lab Invest. 1976 Nov;35(5):444–451. [PubMed] [Google Scholar]
  18. Pétursson G., Nathanson N., Georgsson G., Panitch H., Pálsson P. A. Pathogenesis of visna. I. Sequential virologic, serologic, and pathologic studies. Lab Invest. 1976 Oct;35(4):402–412. [PubMed] [Google Scholar]
  19. SIGURDSSON B., PALSSON P., GRIMSSON H. Visna, a demyelinating transmissible disease of sheep. J Neuropathol Exp Neurol. 1957 Jul;16(3):389–403. doi: 10.1097/00005072-195707000-00010. [DOI] [PubMed] [Google Scholar]
  20. Sonigo P., Alizon M., Staskus K., Klatzmann D., Cole S., Danos O., Retzel E., Tiollais P., Haase A., Wain-Hobson S. Nucleotide sequence of the visna lentivirus: relationship to the AIDS virus. Cell. 1985 Aug;42(1):369–382. doi: 10.1016/s0092-8674(85)80132-x. [DOI] [PubMed] [Google Scholar]
  21. Thormar H., Balzarini J., Holy A., Jindrich J., Rosenberg I., Debyser Z., Desmyter J., De Clercq E. Inhibition of visna virus replication by 2',3'-dideoxynucleosides and acyclic nucleoside phosphonate analogs. Antimicrob Agents Chemother. 1993 Dec;37(12):2540–2544. doi: 10.1128/aac.37.12.2540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Thormar H., Barshatzky M. R., Arnesen K., Kozlowski P. B. The emergence of antigenic variants is a rare event in long-term visna virus infection in vivo. J Gen Virol. 1983 Jul;64(Pt 7):1427–1432. doi: 10.1099/0022-1317-64-7-1427. [DOI] [PubMed] [Google Scholar]
  23. Torsteinsdóttir S., Georgsson G., Gísladóttir E., Rafnar B., Pálsson P. A., Pétursson G. Pathogenesis of central nervous system lesions in visna: cell-mediated immunity and lymphocyte subsets in blood, brain and cerebrospinal fluid. J Neuroimmunol. 1992 Dec;41(2):149–158. doi: 10.1016/0165-5728(92)90065-s. [DOI] [PubMed] [Google Scholar]
  24. Tsai C. C., Follis K. E., Sabo A., Grant R. F., Bartz C., Nolte R. E., Benveniste R. E., Bischofberger N. Preexposure prophylaxis with 9-(2-phosphonylmethoxyethyl)adenine against simian immunodeficiency virus infection in macaques. J Infect Dis. 1994 Feb;169(2):260–266. doi: 10.1093/infdis/169.2.260. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES